Medical Center Pulmovision Ltd.
- Address
- Studentski District, Ulitsa Plovdivsko Pole 11, 1756 Sofia, Bulgaria
Medical Center Pulmovision Ltd. - Pulmonary and Respiratory Disease Research
Medical Center Pulmovision Ltd. is a specialized clinical research facility with extensive expertise in respiratory diseases and pulmonary medicine. The center demonstrates particular strength in conducting multi-phase clinical trials for chronic obstructive pulmonary disease (COPD), asthma, and related respiratory conditions, contributing to the development of innovative therapeutic approaches including novel biologics, combination therapies, and inhaled medications.
- Chronic Obstructive Pulmonary Disease (COPD) trials evaluating novel biologics (itepekimab, tozorakimab), propellant formulations, and exacerbation prevention strategies
- Severe and moderate asthma research focusing on lung function preservation, exacerbation reduction, and long-term disease management with biologics like dupilumab and verekitug
- Bronchiectasis and allergic respiratory conditions including birch pollen-induced allergic rhinoconjunctivitis studies
- Cardiovascular and hematologic oncology trials including heart failure with kidney dysfunction, chronic lymphocytic leukemia, and chronic spontaneous urticaria
The center's research portfolio extends beyond pulmonary medicine to include cardiovascular disease prevention and hematologic malignancies, demonstrating capability in managing complex patient populations with multiple comorbidities. Pulmovision's participation in Phase III registrational studies and long-term safety evaluations reflects their commitment to advancing evidence-based medicine and their infrastructure for supporting comprehensive clinical investigations from early-phase to post-marketing studies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1AstraZeneca AB7active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Pulmovision Ltd.
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO). | AstraZeneca AB | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2024-07-12 | 2026-04-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.